Skip to content
Homepage
Clinic directory

Clinics in Chicago, Illinois

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Chicago, IL

Stem Cell Therapy clinics in Chicago

Chicago supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Northwestern Memorial, Rush University, and University of Chicago, and stem cell practice in the area spans Streeterville, Lincoln Park, and the Gold Coast. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Illinois regulates physician practice through the Department of Financial and Professional Regulation. There is no Illinois-specific stem cell disclosure statute, so federal 21 CFR Part 1271 rules apply. The FDA has issued warning letters to Illinois stem cell operators for unapproved biologics. The 25 Chicago clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Illinois DFPR licensure checks.

18 Clinics, showing page 2 of 2

NovoCell MD
MD on staff

NovoCell MD

Chicago, IL

NovoCell MD, a regenerative-medicine clinic in Chicago, specializes in stem-cell therapy and exosome treatment for musculoskeletal and degenerative conditions. The practice is physician-led and offer…

  • PRP Therapy
  • Arthritis Treatment
  • Erectile Dysfunction (ED) Treatment
  • Stem Cell Therapy
HOUSE22 Med Spa
MD on staff

HOUSE22 Med Spa

Chicago, IL

HOUSE22 Med Spa in Chicago offers a range of regenerative and aesthetic treatments, emphasizing cell-based and orthobiologic approaches alongside conventional injectables and resurfacing procedures. …

  • Stem Cell Therapy
  • NAD IV Therapy
  • Vitamin IV Therapy
  • PRP Therapy
  • IV Therapy
The Stem Cell Hair Restoration and Transplant Clinic

The Stem Cell Hair Restoration and Transplant Clinic

Chicago, IL

The Stem Cell Hair Restoration and Transplant Clinic in Chicago offers advanced regenerative therapies for hair loss, with a focus on stem-cell approaches including mesenchymal stem-cell therapy, pla…

  • PRP Therapy
  • Stem Cell Therapy
15 30 50 results per page

Regulatory context

A note on Illinois's stem cell therapy rules.

Illinois cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Illinois for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Chicago's medical research density also includes legitimate IND-based trials at academic institutions.

  • Illinois Medical Practice Act of 1987, 225 ILCS 60
    Establishes physician licensure and discipline through the Illinois Department of Financial and Professional Regulation Medical Disciplinary Board.
  • Illinois Pharmacy Practice Act, 225 ILCS 85
    Regulates compounding pharmacies aligned with federal 503A and 503B standards relevant to biologic preparation.
  • Illinois Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505
    Empowers the Attorney General to pursue deceptive marketing claims against providers making unsupported clinical statements.

The FDA has issued warning letters to Illinois clinics offering stem cell, exosome, and umbilical cord-derived therapies. The Illinois Department of Financial and Professional Regulation has disciplined physicians for unprofessional conduct related to regenerative medicine. The Illinois Attorney General has used the Consumer Fraud and Deceptive Business Practices Act to pursue clinics making unsupported clinical claims, including class-action partnerships with private plaintiffs. Chicago's market draws ongoing federal attention. No statewide injunction parallel to the California SVF case has been issued, but enforcement risk remains material.

Sources: fda.gov · idfpr.illinois.gov · illinoisattorneygeneral.gov

Stem Cell Therapy in Chicago, answered.

Most stem cell therapies at private Chicago clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Illinois regulates physician practice through the Department of Financial and Professional Regulation.

In the Chicago metro, single-joint autologous bone marrow or adipose injections typically run $4,000 to $12,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $8,000 to $20,000, and full multi-session protocols can reach $15,000 to $40,000. Exosome add-ons range $3,500 to $7,500. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Chicago clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at Northwestern Memorial, Rush University, and University of Chicago periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Chicago or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the Illinois DFPR and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with federal 21 CFR 1271.

Available here

Other Treatments available in Chicago

Explore statewide

Stem Cell Therapy in Illinois

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology